We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 346

Section 8 damages quantified to second generic company
  • Borden Ladner Gervais LLP
  • Canada
  • May 28 2012

This was a second s. 8 damages quantification relating to ramipril; however with a different generic company as plaintiff


Amendments to pleadings allowed alleging that there should be no damages as an alternative, non-infringing process existed
  • Borden Ladner Gervais LLP
  • Canada
  • April 23 2012

The Defendants appealed an order of the Court denying leave to amend their Statements of Defence


Product specificity is the same for different types of claims in listing on the Patent Register
  • Borden Ladner Gervais LLP
  • Canada
  • May 30 2014

Teva brought a motion pursuant to section 6(5)(a) of the Patented Medicines (Notice of Compliance) Regulations relating to the listing of a patent on


Court bifurcates determination of Start Date for section 8 action
  • Borden Ladner Gervais LLP
  • Canada
  • May 30 2014

This is an action commenced pursuant to section 8 of the Patented Medicines (Notice of Compliance) Regulations. Pfizer counterclaimed against Apotex


Intellectual property weekly abstracts bulletin
  • Borden Ladner Gervais LLP
  • Canada
  • July 22 2013

A Member of the Trade-marks Opposition Board (Member) refused the registration of MACDIMSUM for a variety of food and drink items (the Trade-mark


Appeal of prohibition order dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • October 21 2013

The Federal Court issued an order prohibiting Teva from entering the market with its version of zoledronic acid until the expiration of two patents


Other news
  • Borden Ladner Gervais LLP
  • Canada, European Union
  • October 21 2013

Although the details have not been made official, it has been reported that the Canada-European Union Comprehensive Economic and Trade Agreement


Order of prohibition granted in respect of one of two asserted patents
  • Borden Ladner Gervais LLP
  • Canada
  • October 28 2013

Two patents were under consideration by the Court in this application brought pursuant to the Patented Medicines (Notice of Compliance) Regulations


Teva's allegation for section 8 damages not struck on appeal
  • Borden Ladner Gervais LLP
  • Canada
  • October 28 2013

Pfizer appealed a decision refusing to strike Teva’s Statement of Claim to the Federal Court, but the appeal was dismissed because a de novo review


Final injunction permits existing patients to continue to receive infringing medicine
  • Borden Ladner Gervais LLP
  • Canada
  • June 10 2014

This decision relates to the crafting of a final injunction for the sale of STELARA following a finding of infringement. In an earlier trial decision